Medical management of prostatic hyperplasia.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000375:Aging; D001971:Bromocriptine / Q000627:therapeutic use; D003534:Cyproterone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D011467:Prostate / Q000254:growth & development; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D013148:Spironolactone / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D011372:Progestins; D010643:Phenoxybenzamine; D013148:Spironolactone; D001971:Bromocriptine; D003534:Cyproterone